Year: 2020

BERGENBIO CONFIRMS FIRST COVID-19 PATIENT ENROLLED WITH BEMCENTINIB IN ACCORD TRIAL
Bergen, Norway, 8 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO PRESENTS UPDATED CLINICAL DATA FROM TWO PHASE II STUDIES OF BEMCENTINIB IN AML AND MDS PATIENTS AT ASH 2020
Bergen, Norway, 6 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO TO PRESENT AT UPCOMING HEALTHCARE CONFERENCES IN DECEMBER 2020
Bergen, Norway, 3 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 IN INDIA
Bergen, Norway, 24 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO HOSTING VIRTUAL R&D Day TODAY
Bergen, Norway, 06 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT annual SITC meeting
Bergen, Norway, 11 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More- Go to page 1
- Go to page 2
- Go to page 3
- Interim pages omitted …
- Go to page 5
- NEXT